Clinical Trials Browser

Phase 2 × Inflammatory Breast Neoplasms × Trastuzumab × Clear all

NCT00464646 2021-10-25

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

Phase 2 Completed

105 enrolled 17 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT02682693 2021-02-02

GeparX

Phase 2 Completed

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT00006110 2017-07-31

NRR

Phase 2 Completed

82 enrolled 13 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00182793 2017-02-23

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

Phase 2 Completed

32 enrolled 6 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00118053 2013-11-20

Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer

Phase 2 Terminated

5 enrolled 6 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01641406 2012-07-16

NACprotocol

Phase 2 Unknown

Breast Carcinoma In Situ, Carcinoma, Lobular, Inflammatory Breast Neoplasms

NCT00398489 2010-11-09

Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

Phase 2 Unknown

Breast Neoplasms, Inflammatory Breast Neoplasms